Kyle Dennis, co-founder of biotechbreakouts.com, recently joined PreMarket Prep to share his thoughts on Opthotech Corp OPHT 6.87%. According to Dennis, Opthotech will either be a huge hit or miss for traders within the next month.

The Answer Will Come Soon

Dennis pointed out that Opthotech shares have been driven down from above $60 to around $32 following disappointing data from competitor Regeneron Pharmaceuticals Inc REGN 0.76%.

“Regeneron has some negative data with a drug that’s similar to what OPHT has,” Dennis explained.

“Traders and investors are speculating that OPHT is going to have bad data, but I don’t necessarily know that’s the case. I tend to be more positive on the name.”

Opthotech’s data is due out in December, and Dennis believes Opthotech stock will be on the move one way or another.

“It’s either going to be…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!